Published: May 06, 2021
EWING, N.J., May 06, 2021 (GLOBE NEWSWIRE) Antares Pharma, Inc.. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced the appointment of Joseph V. Renda as Senior Vice President of Commercial. Mr. Renda succeeds Patrick Shea who resigned to pursue other interests.
Mr. Renda has had a successful career in leading commercial sales, marketing, and operations at large and mid-sized pharmaceutical companies. Prior to joining Antares, Mr. Renda was Vice President, U.S. Sales Autoimmune and Rare Disease at Mallinckrodt Pharmaceuticals where he led a 200-person organization responsible for over $1B in annual sales and managed 5 unique therapeutic areas and institutional account teams. From 2012 to 2018, he held various positions of increasing responsibility at Novo Nordisk including Marketing Brand Director, Women’s Health Care and leading the commercial operations and effectiveness function responsible for a 150-person sa
Antares Pharma Appoints Joseph Renda as Senior Vice President of Commercial
May 06, 2021 07:15 ET | Source: Antares Pharma, Inc. Antares Pharma, Inc. Ewing, New Jersey, UNITED STATES
EWING, N.J., May 06, 2021 (GLOBE NEWSWIRE) Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced the appointment of Joseph V. Renda as Senior Vice President of Commercial. Mr. Renda succeeds Patrick Shea who resigned to pursue other interests.
Mr. Renda has had a successful career in leading commercial sales, marketing, and operations at large and mid-sized pharmaceutical companies. Prior to joining Antares, Mr. Renda was Vice President, U.S. Sales Autoimmune and Rare Disease at Mallinckrodt Pharmaceuticals where he led a 200-person organization responsible for over $1B in annual sales and managed 5 unique therapeutic areas and institutional account teams. From 2012 to 2018, he held various p
1 Introduction Forward-lookingstatements This Annual Report and the Consolidated Financial Statements contain forward-looking statements as defined under U.S. federal securities laws. Forward-looking statements are based on our current expectations of future events and many of these statements can be identified using terminology such as believes, expects, anticipates, plans, may, will, projects, continues, estimates, potential, opportunity and similar expressions. These forward-looking statements, which include, but are not limited to, statements related to the COVID-19 coronavirus pandemic, our collaboration and license agreement with CSL Behring LLC and the timing of the completion of the transactions contemplated thereby, our beliefs about competitive advantage and the capabilities of our manufacturing facility, our cash runway, the advancement of clinical trials, our intellectual property portfolio, and the impact of regul
Antares Pharma Appoints Dr. Peter Richardson as Executive Vice President, Research and Development and Chief Medical Officer
April 26, 2021 08:30 ET | Source: Antares Pharma, Inc. Antares Pharma, Inc. Ewing, New Jersey, UNITED STATES
EWING, N.J., April 26, 2021 (GLOBE NEWSWIRE) Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced the appointment of Peter Richardson, MRCP, as Executive Vice President, Research and Development and Chief Medical Officer. In this role, Dr. Richardson will oversee the Company’s proprietary research and development programs, including ideation, formulation, clinical operations, pharmacovigilance and medical affairs.
Dr. Richardson has over 25 years of research and development experience in the pharmaceutical and medical device industry. He has created centers of excellence that have enabled and supported product development pipelines encompa